#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Xfsc

This article discusses a clinical trial investigating the effectiveness of two drugs, 2LEBV® and 2LXFS®, in treating fatigue associated with Epstein-Barr Virus (EBV) infection. The study aims to compare these treatments with a placebo to determine their impact on fatigue severity and other symptoms related to EBV infection. This randomized, placebo-controlled, double-blind study will provide valuable insights into potential new treatments for patients suffering from EBV-related fatigue.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-XFSC?

SPECIFIC NUCLEIC ACID SNA-XFSC, also known as SNA-XFSc, is a specialized substance being studied for its potential in treating Epstein-Barr Virus (EBV) infection[1]. It is part of a group of substances called “specific nucleic acids” that are designed to target specific health conditions. In this case, SNA-XFSC is specifically tailored to address chronic fatigue syndrome associated with Epstein-Barr Virus[1].

Target Condition: Epstein-Barr Virus Infection

Epstein-Barr Virus (EBV) is a common virus that can cause various symptoms, including significant fatigue lasting for a month or more. Other symptoms may include:[1]

  • Long-lasting exhaustion even after light exertion
  • Mild fever or elevated body temperature
  • Loss of appetite
  • Sore throat
  • Swollen lymph nodes
  • Muscle weakness and joint pain
  • Memory and attention problems
  • Sleep disturbances

These symptoms can significantly impact a person’s quality of life, making effective treatments crucial.

How SNA-XFSC Works

While the exact mechanism of action is not fully detailed in the available information, SNA-XFSC is a nucleic acid-based treatment. Nucleic acids are the building blocks of DNA and RNA, which are crucial for cellular function[1]. It’s believed that SNA-XFSC may work by interacting with the body’s immune system to help combat the Epstein-Barr Virus more effectively.

Current Clinical Trial

A clinical trial is currently underway to evaluate the effectiveness of SNA-XFSC in treating fatigue associated with EBV infection[1]. The study aims to:

  1. Compare the efficacy of the treatment in reducing fatigue severity
  2. Assess its impact on other symptoms related to EBV infection
  3. Evaluate changes in the immune system, particularly lymphocyte (a type of white blood cell) levels

This trial is randomized, placebo-controlled, and double-blind, which means participants are randomly assigned to either receive the treatment or a placebo, and neither the participants nor the researchers know who is receiving which until the study is completed. This design helps ensure the results are as unbiased as possible.

Potential Benefits

If successful, SNA-XFSC could offer several benefits to patients with EBV infection[1]:

  • Reduction in fatigue severity
  • Improvement in other EBV-related symptoms
  • Potential positive effects on the immune system
  • Better overall quality of life for those suffering from chronic EBV infection

Administration and Dosage

SNA-XFSC is administered as pillules for oromucosal use, which means they are designed to be absorbed through the mucous membrane of the mouth[1]. The maximum daily dose in the study is 380 mg, with a total treatment period of up to 6 months. However, it’s important to note that this dosage is specific to the clinical trial and may not reflect the final recommended dosage if the treatment is approved for general use.

Other Components in the Treatment

The treatment being studied (called 2LXFS) contains several other components alongside SNA-XFSC[1]. These include:

  • Interferon alfa and gamma: Proteins that help regulate immune responses
  • Interleukin-1 and Interleukin-2: Substances that play a role in immune system function
  • Tumor Necrosis Factor-alpha: Another protein involved in inflammation and immune responses
  • Other specific nucleic acids (SNA-XFSA and SNA-XFSB): Likely targeting other aspects of chronic fatigue syndrome

These components work together to potentially provide a comprehensive approach to addressing EBV infection and its symptoms.

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Treatments 2LEBV®, 2LXFS®/2LEBV® combination, and placebo
Target Condition Fatigue in patients with Epstein-Barr Virus infection
Primary Outcome Fatigue severity at 6 months (end of treatment)
Secondary Outcomes Other fatigue dimensions, EBV-related symptoms, immune system changes
Participant Age 12 years and older
Key Inclusion Criteria Significant fatigue for 1+ month, 2+ other EBV symptoms, positive EBV serology
Follow-up Duration 12 months
Key Measurements MFI-20 questionnaire, lymphocyte typing, antibody levels, adverse events

FAQ

  • What is the main goal of this clinical trial? The main goal is to compare the effectiveness of 2LEBV® and 2LXFS®/2LEBV® treatments versus a placebo in reducing fatigue severity for patients with Epstein-Barr Virus infection at the end of the treatment period.
  • Who can participate in this study? Participants must be 12 years or older, experiencing significant fatigue for at least a month, have at least two other EBV-related symptoms, and test positive for EBV antibodies. They should not have received certain treatments recently and must not have severe immunodeficiency diseases.
  • How long does the study last? The study includes follow-up visits at 3 months, 6 months (end of treatment), and 12 months after starting the treatment.
  • What will be measured during the study? The study will measure fatigue severity using the MFI-20 questionnaire, other EBV-related symptoms, changes in lymphocyte typing, immune status, and antibody levels. Safety will also be monitored through adverse events reporting.
  • What is special about the drug 2LXFS®? 2LXFS® contains multiple active substances, including specific nucleic acids targeting chronic fatigue syndrome related to Epstein-Barr Virus, as well as various interferons, interleukins, and other immune-modulating components.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Xfsc

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with various symptoms, including fatigue.
  • Asthenia: A medical term for weakness or lack of energy, often used to describe fatigue associated with viral infections.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind study: A research design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.
  • MFI-20 questionnaire: A tool used to measure fatigue severity across different dimensions, including general fatigue, physical fatigue, and mental fatigue.
  • Lymphocyte typing: A test that identifies and counts different types of white blood cells, which are important for immune function.
  • Immunotherapy: Treatment that uses or enhances the body's immune system to fight diseases.
  • Micro-immunotherapy: A form of therapy that uses low doses of immune-modulating substances to regulate the immune system.
  • Specific Nucleic Acid: A type of genetic material (DNA or RNA) designed to target specific aspects of a disease or condition.
  • Interferon: A group of proteins released by cells in response to viruses, which help to regulate immune responses.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/